JCAR017: Interim Phase I/II data

Interim data from 22 evaluable pediatric patients with relapsed or refractory CD19+ ALL in the open-label, dose-escalation, U.S. Phase I/II PLAT-02 trial showed that JCAR017 led to an MRD-negative com...